Tag
The Schwannomatosis Open Research Collaborative (SORC) is an innovative, community-based research project aimed at utilizing publicly available data to uncover new scientific insights into the rare and understudied genet...
The Biden Administration announced a new requirement, to be implemented as soon as the end of 2025, that the results of all scientific research be made available publicly as soon as that research is published. This chang...
We want the NF Data Portal to be as open and easy to use as possible. To that end, we just launched a new docs site full of documentation to help you learn how to find, share, and use data on the NF Data Portal. Some hig...
We’re thrilled to announce that the NF Annotation App - NF Data Curator - is now available in beta. NF-OSI aims to increase collaboration, fuel important discoveries, make rare disease data more accessible to the communi...
The Gilbert Family Foundation’s (GFF) Gene Therapy Initiative is accepting proposals for high-impact research on gene therapy strategies aimed at addressing the loss of neurofibromin 1 (NF1) gene function in neurofibroma...
Applications are now open for the Children's Tumor Foundation's (CTF) 2021 cycle of Drug Discovery Initiative Registered Reports (DDIRR) award program, a program to fund early stage testing of candidate drug therapies fo...
Do you want to advance the field of neurofibromatosis (NF) and rare diseases? Hack for NF, and be part of developing solutions to end rare diseases! Hackers present rare disease solutions at the 2019 NF Hackathon in San...
In 1990, Dr. Francis S. Collins led the team that discovered the NF1 gene. Now it's your turn to join the team that discovers the cure. The Francis S. Collins Scholars Program in Neurofibromatosis Clinical & Translationa...
NF Data Portal: major updates We’re thrilled to announce the re-release of the NF Data Portal. New features include the ability to explore studies, data, and more with interactive plots; the ability to share your search...
Photo courtesy of National Cancer Institute. Therapeutic highlight: MEK inhibitor approved! After several years of innovative preclinical research and intensive clinical study, selumetinib was granted FDA approval for us...
By Jineta Banerjee and Robert Allaway Drug discovery studies are challenging to conduct for rare diseases because there often isn’t enough relevant biological data. Small, or underpowered, datasets hinder the effectivene...
2nd NF Hackathon results The NF-OSI ran the 2nd ever NF Hackathon in San Francisco this past September. During this collaborative scientific event, participants explored genomic, drug screening, imaging, and other data f...
2nd NF Hackathon: Sept. 13-15 in San Francisco Reminder: A collaborative research event is happening in San Francisco on September 13-15, 2019, one week prior to the 2019 NF Conference. Following in the footsteps of the...
New datasets available on the NF Data Portal The Synodos for NF2 project, led by Drs. Wade Clapp, James Gusella, Scott Plotkin, and Jaishri Blakeley, recently had its final data release. There are several new publicly av...
Contact Information: Frank L. Rice, PhD President, CEO and Chief Scientist Integrated Tissue Dynamics, LLC 7 University Place, Suite B236 Rensselaer, NY 12144 frankrice@intidyn.com www.INTiDYN.com \[Partner Press Release...
The NF Open Science Initiative has had a busy start to 2019. A few updates: New NF1 and NF2-related datasets now available on the NF Data Portal This quarter marks the release of several new datasets that are now availab...
Read the full article in Scientific Data (June 12, 2018). A collaboration of the Neurofibromatosis Therapy Acceleration Program (NTAP), together with Sage Bionetworks, Johns Hopkins, NCATS and the University of Florida P...
